Deucravacitinib for psoriasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Feb 2021: Trial registered, NCT04772079
  2. 23 Mar 2021: Trial started, NCT04772079

The trials

NCT04772079: A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

State
Under way
Phase
Phase 3
People
153 planned
Started
23 Mar 2021
Primary completion
1 Jan 2029
Arms
Active treatment deucravacitinib standard dose, Active treatment deucravacitinib half-standard dose
Results
None posted
  1. 26 Feb 2021: Trial registered
  2. 23 Mar 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Sotyktu.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.